Anti-RPGF5/ RAPGEF5/ GFR monoclonal antibody

Anti-RPGF5/ RAPGEF5/ GFR antibody for FACS & in-vivo assay

Target products collectionGo to RAPGEF5/RAPGEF5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2590-Ab-1/ GM-Tg-hg-MP2590-Ab-2Anti-Human RAPGEF5 monoclonal antibodyHuman
GM-Tg-rg-MP2590-Ab-1/ GM-Tg-rg-MP2590-Ab-2Anti-Rat RAPGEF5 monoclonal antibodyRat
GM-Tg-mg-MP2590-Ab-1/ GM-Tg-mg-MP2590-Ab-2Anti-Mouse RAPGEF5 monoclonal antibodyMouse
GM-Tg-cynog-MP2590-Ab-1/ GM-Tg-cynog-MP2590-Ab-2Anti-Cynomolgus/ Rhesus macaque RAPGEF5 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2590-Ab-1/ GM-Tg-felg-MP2590-Ab-2Anti-Feline RAPGEF5 monoclonal antibodyFeline
GM-Tg-cang-MP2590-Ab-1/ GM-Tg-cang-MP2590-Ab-2Anti-Canine RAPGEF5 monoclonal antibodyCanine
GM-Tg-bovg-MP2590-Ab-1/ GM-Tg-bovg-MP2590-Ab-2Anti-Bovine RAPGEF5 monoclonal antibodyBovine
GM-Tg-equg-MP2590-Ab-1/ GM-Tg-equg-MP2590-Ab-2Anti-Equine RAPGEF5 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2590-Ab-1/ GM-Tg-hg-MP2590-Ab-2; GM-Tg-rg-MP2590-Ab-1/ GM-Tg-rg-MP2590-Ab-2;
GM-Tg-mg-MP2590-Ab-1/ GM-Tg-mg-MP2590-Ab-2; GM-Tg-cynog-MP2590-Ab-1/ GM-Tg-cynog-MP2590-Ab-2;
GM-Tg-felg-MP2590-Ab-1/ GM-Tg-felg-MP2590-Ab-2; GM-Tg-cang-MP2590-Ab-1/ GM-Tg-cang-MP2590-Ab-2;
GM-Tg-bovg-MP2590-Ab-1/ GM-Tg-bovg-MP2590-Ab-2; GM-Tg-equg-MP2590-Ab-1/ GM-Tg-equg-MP2590-Ab-2
Products NameAnti-RAPGEF5 monoclonal antibody
Formatmab
Target NameRAPGEF5
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-RAPGEF5 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species RPGF5/ RAPGEF5/ GFR VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2590
    Target NameRAPGEF5
    Gene ID9771,217944,362799,711698,100855786,101088478,519566,100067593
    Gene Symbol and Synonyms4932413M22,D030051B22Rik,GFR,mKIAA0277,mmr-gef,MR-GEF,MRGEF,RAPGEF5,REPAC,RGD1562891,rMR-GEF
    Uniprot AccessionQ92565,P83900
    Uniprot Entry NameRPGF5_HUMAN,RPGF5_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000136237
    Target ClassificationN/A

    The target: RAPGEF5, gene name: RAPGEF5, also named as GFR, MR-GEF, REPAC. Members of the RAS (see HRAS; MIM 190020) subfamily of GTPases function in signal transduction as GTP/GDP-regulated switches that cycle between inactive GDP- and active GTP-bound states. Guanine nucleotide exchange factors (GEFs), such as RAPGEF5, serve as RAS activators by promoting acquisition of GTP to maintain the active GTP-bound state and are the key link between cell surface receptors and RAS activation (Rebhun et al., 2000 [PubMed 10934204]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.